Clinical Trials of DNA and Recombinant Adenovector (rAd) Vaccines for HIV
Retrovirology volume 2, Article number: S61 (2005)
Gene-based vaccine delivery is an important strategy for induction of T cell responses that may be critical for a successful AIDS vaccine. Despite promising results in animal models, evidence of immune responses to DNA and rAd vaccines in humans has been limited.
Materials and methods
Three Phase I studies have evaluated a series of DNA and rAd vaccine candidates expressing constructs encoding clades A, B, and C Envelope and clade B Gag and Pol with or without Nef, as fusion proteins or individually.
T cell and antibody responses are detected by IFN-α ELISpot and FACS detection of intracellular IL-2 or IFN-α in the large majority of vaccinees. Env peptide pools elicit the strongest response, but the 6-plasmid and rAd product also induced robust responses to Gag, Pol, and Nef. Both T cell and humoral responses were dose dependent. The T cell responses induced by DNA are detectable for at least 52 weeks, and the pattern of cytokine expression evolves over time with fewer IFN-γ and more IL-2 producing T cells at one year.
DNA and rAd5 vaccine candidates are well tolerated and induce broad, durable immune responses. The combination will be tested in Phase II trials beginning 4Q2005.
About this article
Cite this article
Graham, B.S. Clinical Trials of DNA and Recombinant Adenovector (rAd) Vaccines for HIV. Retrovirology 2 (Suppl 1), S61 (2005). https://doi.org/10.1186/1742-4690-2-S1-S61